ThursdayOct 01, 2026 12:00 pm

Regentis Biomaterials Is Addressing the ‘Short-Term Relief, Long-Term Failure’ Problem in Knee Cartilage Repair

One of the challenges in cartilage repair is that some procedures can provide meaningful short-term pain relief without restoring durable, functional cartilage capable of withstanding the demands of an active joint. Regentis Biomaterials is taking a regenerative approach with GelrinC, a cell-free, off-the-shelf hydrogel designed to temporarily fill cartilage defects while guiding the healthy surrounding tissue to regenerate new, natural and highest hyalin quality cartilage. Recent long-term MRI and peer-reviewed clinical data have provided additional evidence supporting the quality and durability of knee cartilage regenerated with GelrinC, as the company advances its U.S. pivotal trial and commercialization efforts in Europe.…

Continue Reading

ThursdayOct 01, 2026 10:00 am

Health Insurance Has Spiked 78% in the US Since 2011

Surging health insurance costs have compelled even healthcare workers to stop getting coverage not only for themselves but also for their staff at private facilities. Premiums climbed 78% between 2011 and 2024, a JAMA study shows. The spiraling costs affecting ordinary Americans haven’t spared healthcare professionals. KFF News provides the example of Ashley Durham, a pharmacist, and her husband Doctor Joshua Durham. The couple owns and runs a medical practice in Idaho, and the rising health insurance costs have compelled them to drop their own policy this year. To get the treatment they need, they have been making withdrawals from…

Continue Reading

WednesdaySep 30, 2026 12:00 pm

Nano-X Imaging CEO and Directors Report Open-Market Share Purchases

Nano-X Imaging Ltd. (NASDAQ: NNOX) today announced that recent SEC Form 4 filings disclosed open-market purchases of the company's ordinary shares by Chief Executive Officer Erez Meltzer and Board Director Dan Suesskind. These purchases are in addition to other open-market purchases of Nano-X ordinary shares by company insiders including Erez Meltzer, Dan Suesskind and Board Director Nogah Keinan reported in recent months. Together, the purchases represent Nano-X ordinary shares acquired in the open market by the company's CEO and members of its Board of Directors. Additional information regarding the transactions is available in the respective SEC filings. About Nanox  Nanox…

Continue Reading

TuesdaySep 29, 2026 11:15 am

Earth Science Tech Inc. (ETST) Driving Sustainable Growth on New Technologies, In-House Expertise

Earth Science Tech is leveraging AI and other technology, along with the expertise of a focused IT department, to drive sustainable growth and ensure long-term value The company uses technology to drive down costs, improve operational efficiencies, and expand profit margins within its pharmacy and telemedicine platforms ETST also utilizes technology in marketing to increase patient and customer retention and drive brand loyalty During the recent Annual Meeting of Shareholders, CTO Chris Rose explained the company’s tech stack and developments that have enabled it to offer its in-house tools to other clinics as a white-label service Earth Science Tech (OTCQB:…

Continue Reading

TuesdaySep 29, 2026 10:30 am

Finding What the Scan Already Captured: Nanox Advances Its AI Business on Two Fronts

Approximately 86,000 vertebral fragility fractures occur annually in the UK, with most remaining undiagnosed. Nanox.AI has signed an exclusive three-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution, with minimum annual license commitments built into the deal. A separate optimization project with Intel demonstrates a path for Nanox.AI’s imaging AI framework to run inference locally on hospital hardware rather than relying entirely on the cloud. A CT scan ordered to answer one clinical question may capture additional anatomical information beyond the original indication. In certain cases, routine CT imaging can include information related to the spine, coronary…

Continue Reading

TuesdaySep 29, 2026 10:30 am

Survey Shows Most American Adults Support Vaccination, But Uncertainty is Widespread

According to a new survey conducted by NFID (National Foundation for Infectious Diseases), the vast majority of American adults, 77%, support vaccines. However, there is widespread uncertainty regarding which specific vaccines people need.  The survey, which is conducted annually, sought to gather the views of the public across the country on matters of vaccination. The survey largely focused on vaccines designed for respiratory conditions, specifically flu, RSV (respiratory syncytial virus), pneumococcal disease, and Covid-19.  The survey results showed that while Americans hold positive views about vaccines, there is a gap in their clarity on the specific vaccines they need to…

Continue Reading

MondaySep 28, 2026 2:00 pm

Regentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage Care

Orthopedic practice is moving away from a model that manages knee pain until the joint fails, to early structural intervention - a shift that raises the bar for what a cartilage repair product has to deliver. Regentis' GelrinC is an acellular hydrogel implant designed to erode in a controlled, synchronized manner as surrounding cells regenerate hyaline-like cartilage, with Phase II data showing approximately 100% greater KOOS improvement than microfracture at two years. With CE Mark approval in Europe, pivotal U.S. trial enrollment targeted for completion by approximately year end 2026, and platform work extending toward moderate osteoarthritis, the company is…

Continue Reading

MondaySep 28, 2026 10:00 am

Researchers in South Korea Identify New Protein That Controls Brain Cancer Growth

Glioblastoma is the deadliest form of brain cancer due to its aggressive growth rate. Most patients don’t survive for more than a year after diagnosis, and the disease quickly develops resistance to existing treatments. Scientists have been racing to find ways to treat this malignancy and prolong patient survival.  Now, a team of researchers in South Korea have found a novel protein that acts as the switch regulating glioblastoma’s growth. The researchers also identified a compound that can turn off this switch, effectively slowing down the cancer’s growth and reducing the size of tumors.  Doctor Han Tae-su, who led the…

Continue Reading

FridaySep 25, 2026 9:45 am

Nanox’s Integrated Imaging Ecosystem: Expanding Access to 3D Imaging and Diagnostics

Roughly two-thirds of the world’s population lacks access to basic imaging technology, and the radiologist workforce gap is just as stark. Nanox brings together Nanox.ARC, Nanox.AI, Nanox.CLOUD, Nanox.MARKETPLACE, USARAD Holdings and Nanox Health IT as part of its broader imaging ecosystem. Commercial activity is beginning to build, with second-quarter revenue of $4.2 million. Advanced medical imaging has transformed diagnosis, yet access to it remains remarkably uneven. Roughly two-thirds of the world’s population lacks access to basic imaging technology, a figure widely attributed to the World Health Organization, and the workforce gap is just as stark: an estimated 1.9 radiologists per…

Continue Reading

ThursdaySep 24, 2026 10:30 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing

The FDA IND approval marks a pivotal step for the company's lead compound, known as Lucid-MS. What sets Quantum BioPharma’s proprietary treatment apart from most existing MS therapies is its mechanism. Lucid-MS previously completed phase 1 clinical trials, showing a favorable safety profile and being well tolerated. A green light from the U.S. Food and Drug Administration (“FDA”) can turn years of laboratory work into a real shot at treating patients, and that is exactly what just happened for one biopharmaceutical company. Quantum BioPharma (NASDAQ: QNTM), a company focused on neurodegenerative and metabolic disorders, announced that the FDA has approved…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000